Johnson & Johnson: Lymphoma, Follicular trials
The registry lists 11 Lymphoma, Follicular studies with Johnson & Johnson as lead sponsor. 0 are open to participants now and 2 have results posted.
Phase 1 5Phase 2 4Phase 3 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular LymphomaTerminatedNCT02413489Phase 2Results posted
- A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin LymphomaCompletedNCT01974440Phase 3Results posted
- Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in LymphomaWithdrawnNCT02743546Phase 1
- A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell MalignanciesTerminatedNCT02454270Phase 1
- Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell MalignancyCompletedNCT02381080Phase 1
- A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative ColitisCompletedNCT01959282Phase 2
- An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular LymphomaTerminatedNCT01902862Phase 2
- A Study to Evaluate the Pharmacokinetics of JNJ-38518168 in Patients With Mild and Moderate Hepatic Impairment Compared With Patients With Normal Hepatic FunctionCompletedNCT01863784Phase 1
- A Long-term Extension Study of PCI-32765 (Ibrutinib)Active, not recruitingNCT01804686Phase 3
- A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular LymphomaCompletedNCT01779791Phase 2
- A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin LymphomaCompletedNCT01569750Phase 1